Alefacept FDA Link

A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.

Also Known As:

Amevive; LFA-3 IgG(1) Fusion Protein; LFA-3 IgG1 Fusion Protein; LFA 3 IgG1 Fusion Protein

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - CD58 Antigens: 134
        Alefacept: 234
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - CD58 Antigens: 134
        Alefacept: 234
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoglobulin Isotypes: 1085
        Immunoglobulin G: 58863
        Alefacept: 234
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoglobulin Isotypes: 1085
        Immunoglobulin G: 58863
        Alefacept: 234
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - CD58 Antigens: 134
        Alefacept: 234
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoglobulin Isotypes: 1085
        Immunoglobulin G: 58863
        Alefacept: 234
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - Alefacept: 234

Harold F Farber Selected Research

Harold F Farber Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure